These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 30528604)
1. Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles. Cheng B; Gao F; Maissy E; Xu P Acta Biomater; 2019 Jan; 84():378-390. PubMed ID: 30528604 [TBL] [Abstract][Full Text] [Related]
2. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624 [TBL] [Abstract][Full Text] [Related]
3. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748 [TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525 [TBL] [Abstract][Full Text] [Related]
5. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery. Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700 [TBL] [Abstract][Full Text] [Related]
6. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700 [TBL] [Abstract][Full Text] [Related]
7. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition. Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637 [TBL] [Abstract][Full Text] [Related]
8. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment. Hu G; Chun X; Wang Y; He Q; Gao H Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810 [TBL] [Abstract][Full Text] [Related]
9. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine. Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129 [TBL] [Abstract][Full Text] [Related]
10. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model. Tan ML; Friedhuber AM; Dass CR J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686 [TBL] [Abstract][Full Text] [Related]
11. A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy. Niu S; Williams GR; Wu J; Wu J; Zhang X; Chen X; Li S; Jiao J; Zhu LM J Nanobiotechnology; 2019 Sep; 17(1):95. PubMed ID: 31506085 [TBL] [Abstract][Full Text] [Related]
12. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219 [TBL] [Abstract][Full Text] [Related]
13. Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer. Lee R; Choi YJ; Jeong MS; Park YI; Motoyama K; Kim MW; Kwon SH; Choi JH Bioconjug Chem; 2020 Mar; 31(3):923-932. PubMed ID: 32027493 [TBL] [Abstract][Full Text] [Related]
14. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer. Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487 [TBL] [Abstract][Full Text] [Related]
15. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles. Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300 [TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784 [TBL] [Abstract][Full Text] [Related]
17. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid. Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317 [TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy. Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy. Wu J; Tang C; Yin C Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232 [TBL] [Abstract][Full Text] [Related]
20. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer. Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]